Cancer Letters

Cancer Letters

Volume 44, Issue 3, March 1989, Pages 221-226
Cancer Letters

Long-term carcinogenicity of cyclophosphamide in two mouse strains with different spontaneous leukemia incidence

https://doi.org/10.1016/0304-3835(89)90065-7Get rights and content

Abstract

The aim of the present study was to investigate to what extent the induction of leukemia by the carcinogenic agent cyclophosphamide (CPA) might be influenced by the genetic predisposition. CPA was s.c. administered at 26 mg/kg and 13 mg/kg weekly for lifetime to AKR mice which are genetically predisposed to develop leukemias, and to NMRI mice, that exhibit a low spontaneous leukemia rate. CPA dose-dependently increased the median life span in AKR mice by 27% and 76% (P < 0.001), and decreased the incidence in leukemias by 17% and 37% (P < 0.01), respectively. In NMRI mice, CPA significantly increased the incidence of leukemias by 46% at the low dose (P < 0.02) and 26% at the high dose (P < 0.03), respectively. The apparently parallel observations of the lower leukemia incidences following the higher CPA-dosage in both strains probably are related to different mechanisms of action: in the susceptible, genetically determined AKR mice the therapeutic effect of CPA prevailed its carcinogenic potential and the genetic host factors whereas in the resistant NMRI mice the cytotoxic efficacy of CPA reduced its carcinogenicity at the higher dosage.

References (18)

  • H. Lynch et al.

    Genetic/epidemiological findings in a study of smoking-associated tumors

    Cancer Genet. Cytogenet.

    (1982)
  • D. Schmähl et al.

    Occurrence of second tumors in man after anticancer drug treatment

    Cancer Treat. Rev.

    (1982)
  • G. Bekesi et al.

    Treatment of spontaneous leukemia in AKR mice with chemotherapy, immunotherapy, or interferon

    Cancer Res.

    (1976)
  • O.J. Dunn

    Multiple comparison using rank sums

    Technometrics

    (1964)
  • L. Gross

    “Spontaneous” leukemia developing in C3H mice following inoculation, in infancy, with AK-leukemic extracts or AK embryos

  • D. Harnden

    Genetic predisposition for cancer risks in man

  • International Agency for Research on Cancer
  • G. Medoff et al.

    Potentiation of anticancer agents by amphotericin B

    J. Natl. Cancer Inst.

    (1981)
  • R. Peto et al.

    Guidelines for simple, sensitive significance tests for carcinogenic effects in long-term animal experiments

There are more references available in the full text version of this article.

Cited by (5)

View full text